Arcturus Therapeutics (ARCT) Lowered to “Hold” at Zacks Investment Research

Arcturus Therapeutics (ARCT) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Arcturus Therapeutics (NASDAQ:ARCT) from a buy rating to a hold rating in a research report sent to investors on Tuesday.

According to Zacks, “Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. “

ARCT has been the topic of several other reports. WBB Securities raised Arcturus Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, September 20th. Brookline Capital Management reissued a buy rating on shares of Arcturus Therapeutics in a research report on Thursday, September 27th. Finally, ValuEngine lowered Arcturus Therapeutics from a buy rating to a hold rating in a research report on Monday, October 8th. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Arcturus Therapeutics currently has an average rating of Buy and an average target price of $8.63.

Shares of Arcturus Therapeutics stock opened at $5.45 on Tuesday. The firm has a market cap of $55.06 million, a PE ratio of -1.54 and a beta of 1.93. Arcturus Therapeutics has a 12-month low of $4.11 and a 12-month high of $10.43.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.04. The company had revenue of $3.42 million for the quarter, compared to analyst estimates of $3.75 million. Research analysts anticipate that Arcturus Therapeutics will post -1.9 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of ARCT. JPMorgan Chase & Co. increased its position in Arcturus Therapeutics by 91.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,744 shares of the biotechnology company’s stock worth $148,000 after purchasing an additional 8,008 shares during the last quarter. BlackRock Inc. acquired a new position in Arcturus Therapeutics in the 2nd quarter worth about $169,000. Worth Venture Partners LLC acquired a new position in Arcturus Therapeutics in the 3rd quarter worth about $290,000. Finally, ARK Investment Management LLC increased its position in Arcturus Therapeutics by 45.0% in the 3rd quarter. ARK Investment Management LLC now owns 773,772 shares of the biotechnology company’s stock worth $6,840,000 after purchasing an additional 239,999 shares during the last quarter. 10.09% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.

Recommended Story: Analyst Ratings Trading

Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment